Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 5, 2012, Pages 535-542

  Buti, María ^a   Morillas, Rosa Maria ^b   Prieto, Martín ^d,j   Diago, Moisés ^e   Pérez, Juan ^f   Solà, Ricard ^c   Bonet, Lucía ^g   Palau, Antonio ^h,j   Testillano, Milagros ⁱ   García Samaniego, Javier ^j   Rodríguez, Manuel ^k  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^g HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^h HOSPITAL GENERAL DE CASTELLÓN   (Spain)

ⁱ HOSPITAL DE CRUCES   (Spain)

^j INSTITUTO DE SALUD CARLOS III   (Spain)

^k HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

more..

Author keywords

chronic hepatitis B; clinical practice; entecavir

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CAUCASIAN; CLINICAL PRACTICE; COHORT ANALYSIS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; EPIGASTRIC PAIN; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INSOMNIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOOD DISORDER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG EVALUATION; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84859436515     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283511287     Document Type: Article

References (23)

1. World Health Organization. Fact sheet No. 204. http://www.who.int/ mediacentre/factsheets/fs204/en/. [Accessed 12 December 2011].
2. European Centre for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe 2010. Stockholm: European Centre for Disease Prevention and Control; http:// www.ecdc.europa.eu/ en/publications/Publications/1011-SUR-Annual- Epidemiological-Report-on- Communicable-Diseases-in-Europe.pdf. [Accessed 12 December 2011].
3. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
4. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686. (Pubitemid 43374518)
5. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97:265-272.
6. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539. (Pubitemid 46374607)
7. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2:263-283.
8. Wright TL, Avunduk C, Dienstag JL, Freston JW, Jacobson IM, Nord HJ, Sherman M. Advancing patient care: integrating new data. Am J Gastroenterol 2006; 101 (Suppl 1):S32-S39. (Pubitemid 43381699)
9. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335-352.
10. Lau GKK. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver Int 2010; 30:512-520.
11. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
12. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010. (Pubitemid 43357804)
13. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020. (Pubitemid 43357805)
14. World Health Organization. Toxicity Grading Scale for Determining the Severity of Adverse Events. http://www.icssc.org/Documents/Resources/ AEManual2003AppendicesFebruary-06-2003%20final.pdf [Accessed 12 December 2011].
15. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133:1437-1444. (Pubitemid 350029745)
16. Chang TT, Lai CL, Yoon SK, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51:422-430.
17. Shouval D, Lai CL, Chang TT, Gadano A, Wu SS, Halota W, et al. Three years of entecavir (ETV) re-treatment of HBeAg( - ) ETV patients who previously discontinued treatment: results from study ETV-901. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 31 October-4 November 2008; San Francisco, CA, USA. Poster 927. http://www.natap.org/2008/ AASLD/AASLD-33.htm. [Accessed 12 December 2011].
18. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49:1503-1514.
19. Tenney DJ, Pokorowski KA, Rose RE, Baldick CJ, Eggers BJ, Fang J, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naïve patients. Oral presentation at the 44th Annual Meeting of the European Association for the Study of Liver (EASL); 22-26 April 2009; Copenhagen, Denmark. http://www.natap.org/2009/EASL/EASL-31.htm. [Accessed 12 December 2011].
20. Lampertico P, Viganò M, Soffredini R, Facchetti F, Minola E, Suter F, et al. Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice: the Italian multicenter experience. 61st Annual Meeting of American Association for the Study of Liver Diseases (AASLD), 29 October-2 November 2010. Abstract 391. http://trs.scivee.tv/node/1238. [Accessed 12 December 2011].
21. Reijnders JG, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52:493-500.
22. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-Naïve chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011; 106:1264-1271.
23. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137:2002-2009.